Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 6
1988 4
1989 11
1990 15
1991 30
1992 30
1993 18
1994 18
1995 22
1996 14
1997 15
1998 25
1999 24
2000 16
2001 16
2002 16
2003 17
2004 21
2005 20
2006 37
2007 35
2008 29
2009 35
2010 43
2011 37
2012 28
2013 67
2014 114
2015 130
2016 146
2017 149
2018 129
2019 131
2020 141
2021 175
2022 153
2023 143
2024 181
2025 184
2026 87

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,245 results

Results by year

Filters applied: . Clear all
Page 1
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; FIBRONEER-IPF Trial Investigators. Richeldi L, et al. N Engl J Med. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. N Engl J Med. 2025. PMID: 40387033 Clinical Trial.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R; 1404-0043 Trial Investigators. Sanyal AJ, et al. N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7. N Engl J Med. 2024. PMID: 38847460 Free article. Clinical Trial.
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease.
Garrido-Trigo A, Corraliza AM, Veny M, Dotti I, Melón-Ardanaz E, Rill A, Crowell HL, Corbí Á, Gudiño V, Esteller M, Álvarez-Teubel I, Aguilar D, Masamunt MC, Killingbeck E, Kim Y, Leon M, Visvanathan S, Marchese D, Caratù G, Martin-Cardona A, Esteve M, Ordás I, Panés J, Ricart E, Mereu E, Heyn H, Salas A. Garrido-Trigo A, et al. Nat Commun. 2023 Jul 26;14(1):4506. doi: 10.1038/s41467-023-40156-6. Nat Commun. 2023. PMID: 37495570 Free PMC article.
Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression.
Abedini A, Levinsohn J, Klötzer KA, Dumoulin B, Ma Z, Frederick J, Dhillon P, Balzer MS, Shrestha R, Liu H, Vitale S, Bergeson AM, Devalaraja-Narashimha K, Grandi P, Bhattacharyya T, Hu E, Pullen SS, Boustany-Kari CM, Guarnieri P, Karihaloo A, Traum D, Yan H, Coleman K, Palmer M, Sarov-Blat L, Morton L, Hunter CA, Kaestner KH, Li M, Susztak K. Abedini A, et al. Nat Genet. 2024 Aug;56(8):1712-1724. doi: 10.1038/s41588-024-01802-x. Epub 2024 Jul 24. Nat Genet. 2024. PMID: 39048792 Free PMC article.
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ; FIBRONEER-ILD Trial Investigators. Maher TM, et al. N Engl J Med. 2025 Jun 12;392(22):2203-2214. doi: 10.1056/NEJMoa2503643. Epub 2025 May 19. N Engl J Med. 2025. PMID: 40388329 Clinical Trial.
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Heymach JV, et al. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28. N Engl J Med. 2025. PMID: 40293180 Clinical Trial.
Targeting cancer with small-molecule pan-KRAS degraders.
Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, Zollman D, Wijaya A, Mischerikow N, Hasenoehrl C, Prokofeva P, Arnhof H, Arce-Solano S, Bell S, Boeck G, Diers E, Frost AB, Goodwin-Tindall J, Karolyi-Oezguer J, Khan S, Klawatsch T, Koegl M, Kousek R, Kratochvil B, Kropatsch K, Lauber AA, McLennan R, Olt S, Peter D, Petermann O, Roessler V, Stolt-Bergner P, Strack P, Strauss E, Trainor N, Vetma V, Whitworth C, Zhong S, Quant J, Weinstabl H, Kuster B, Ettmayer P, Ciulli A. Popow J, et al. Science. 2024 Sep 20;385(6715):1338-1347. doi: 10.1126/science.adm8684. Epub 2024 Sep 19. Science. 2024. PMID: 39298590
Spatial transcriptomic characterization of pathologic niches in IPF.
Mayr CH, Santacruz D, Jarosch S, Bleck M, Dalton J, McNabola A, Lempp C, Neubert L, Rath B, Kamp JC, Jonigk D, Kühnel M, Schlüter H, Klimowicz A, Doerr J, Dick A, Ramirez F, Thomas MJ. Mayr CH, et al. Sci Adv. 2024 Aug 9;10(32):eadl5473. doi: 10.1126/sciadv.adl5473. Epub 2024 Aug 9. Sci Adv. 2024. PMID: 39121212 Free PMC article.
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
2,245 results